New Treatment Options for Patients With Bladder Cancer

Presented by:
Thomas W. Flaig
Search for other papers by Thomas W. Flaig in
Current site
Google Scholar
Restricted access

Bladder cancer is not rare—in men, it is the fourth most common cancer and the eighth leading cause of cancer-related death. The emergence of new systemic therapies, approval of PD-1 and PD-L1 inhibitors, and progress in the development of biomarkers have revolutionized the treatment of this urologic malignancy. The current NCCN Guidelines, which reflect the most up-to-date, evidence-based data relating to the evaluation and management of bladder cancer, support the incorporation of some of these novel therapeutics into clinical practice.

Disclosures: Dr. Flaig has disclosed receiving grant/research support from Agensys, Inc., Astellas Pharma US, Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech, Inc., Janssen Pharmaceutica Products, LP, Merck & Co., Inc., sanofi-aventis U.S., and Seattle Genetics, Inc; serving as a scientific advisor for Janssen Pharmaceutica Products, LP, and Seattle Genetics, Inc.; and receiving equity interest/stock options in and intellectual property rights for Aurora Oncology.

Correspondence: Thomas W. Flaig, MD, University of Colorado, Mail Stop F520, 13001 East 17th Place, Aurora, CO 80045. Email:
  • Collapse
  • Expand
  • 1.

    Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022. CA Cancer J Clin 2022;72:733.

  • 2.

    Lawrence MS, Stojanov P, Polak P, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013;499:214218.

  • 3.

    Flaig TW, Spiess PE, Abern M, et al. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Bladder Cancer. Version 1.2022. Accessed March 31, 2022. Available at

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 4.

    Balar AV, Kamat AM, Kulkarni GS, et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol 2021;22:919930.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 5.

    Gill J, Prasad V. Pembrolizumab for non–muscle-invasive bladder cancer—a costly therapy in search of evidence. JAMA Oncol 2021;7:501502.

  • 6.

    Steinberg RL, Thomas LJ, Brooks N, et al. Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer. J Urol 2020;203:902909.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017;376:10151026.

  • 8.

    Bajorin DF, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N Engl J Med 2021;384:21022114.

  • 9.

    Powles T, Park SH, Voog E, et al. Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma. N Engl J Med 2020;383:12181230.

  • 10.

    Powles T, Rosenberg JE, Sonpavde GP, et al. Enfortumab vedotin in previously treated advanced urothelial carcinoma. N Engl J Med 2021;384:11251135.

  • 11.

    Tagawa ST, Balar AV, Petrylak DP, et al. TROPHY-U-01: a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. J Clin Oncol 2021;39:24742485.

    • Crossref
    • PubMed
    • Search Google Scholar
    • Export Citation
  • 12.

    Loriot Y, Necchi A, Park SH, et al. Erdafitinib in locally advanced or metastatic urothelial carcinoma. N Engl J Med 2019;381:338348.

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 2571 403 20
PDF Downloads 1633 147 7
EPUB Downloads 0 0 0